E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hereditary Angioedema Type I or II |
|
E.1.1.1 | Medical condition in easily understood language |
Hereditary Angioedema is a genetic condition characterised by swelling of tissues. These swellings can occur on any part of the body. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10080956 |
E.1.2 | Term | Hereditary angioedema type I |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 24.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10080960 |
E.1.2 | Term | Hereditary angioedema type II |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the clinical efficacy of prophylactic treatment with KVD824 compared with placebo in preventing hereditary angioedema (HAE) attacks. |
|
E.2.2 | Secondary objectives of the trial |
To further characterize the clinical efficacy of KVD824.
To investigate the safety and tolerability of KVD824. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Male or female subjects 18 years of age and older.
2) Confirmed diagnosis of HAE type I or II at any time in the medical history:
a) Documented clinical history consistent with HAE (subcutaneous or mucosal, nonpruritic swelling episodes without accompanying urticaria) AND EITHER
b) Diagnostic testing results obtained prior to randomization that confirm HAE Type I or II: C1-INH functional level <40% of the normal level. Subjects with functional C1-INH level 40-50% of the normal level may be enrolled if they also have a C4 level below the normal range. Testing may be obtained from central or local laboratories or obtained from documented historical testing results. Subjects may be retested at any time prior to randomization if results are incongruent with clinical history or believed by the Investigator to be confounded by therapeutic C1-INH use, OR
c) Documented genetic results that confirm known mutations for HAE Type I or II.
3) Subject has access to and ability to use conventional treatment for HAE attacks.
4) Subject is willing to cease any current medications being taken for HAE prophylaxis and Investigator determines that doing so would not place the subject at any undue safety risk. NOT APPLICABLE FOR GERMANY
5) Subject’s last dose of attenuated androgens was at least 28 days prior to first dose of IMP.
6) During the Run-in Period subject meets one of the following criteria:
a) Two Investigator-confirmed attacks in the first 4-week period.
b) Three Investigator-confirmed attacks in ≤8 weeks.
7) Subjects who are fertile and heterosexually active must adhere to contraception requirements throughout the trial as follows:
a) Female subjects must agree to use at least one highly effective contraception method from the Screening Visit until the end of the trial. Highly effective methods of contraception include:
i) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral/injectable/implantable (hormonal contraception that contains estrogen including ethinylestradiol is excluded per Exclusion 4).
ii) Intrauterine device (IUD).
iii) Intrauterine hormone–releasing system (IUS).
iv) Bilateral tubal occlusion.
v) Vasectomized partner (provided that the partner is the sole sexual partner of the female subject of childbearing potential and that the vasectomized partner has received medical assessment of surgical success).
b) Male subjects with a female partner of childbearing potential must agree to use condoms for the entire Treatment Period AND for 90 days following the final dose of investigational medicinal product (IMP). Female partners are encouraged to use contraception as outlined in Inclusion 7a) from the Screening Visit until the end of the trial. Hormonal contraception that contains estrogen including ethinylestradiol is acceptable for the female partner.
8) Subjects who are not fertile or not sexually active, as defined below, do not require contraception.
a) Subjects who refrain from heterosexual intercourse during the trial if the reliability of the heterosexual abstinence has been evaluated in relation to the duration of the clinical trial and is the preferred and usual lifestyle of the subject.
b) Male subjects who are surgically sterile (e.g. vasectomized with medical assessment of surgical success).
c) Female subjects who are surgically sterile (e.g. status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months.
9) Subjects must be able to swallow trial tablets whole.
10) Subjects assessed by the Investigator must be able to appropriately receive and store IMP, and be able to read, understand, and complete the eDiary.
11) Investigator believes that the subject is willing and able to adhere to all protocol requirements.
12) Subject provides signed informed consent and is willing and capable of complying with trial requirements and procedures.
13) Subject has received a full COVID-19 vaccination series prior to Screening.
|
|
E.4 | Principal exclusion criteria |
1) Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
2) A clinically significant history of poor response to C1-INH therapy or plasma kallikrein inhibitor therapy, for the management of HAE, in the opinion of the Investigator.
3) Use of angiotensin-converting enzyme (ACE) inhibitors after the Screening Visit or within 7 days prior to randomization.
4) Any estrogen containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) after the Screening Visit or within 7 days prior to randomization.
5) Use of narrow therapeutic index drugs metabolized by CYP3A4 or CYP2C9 or transported by OAT1, OCT2, and OATP1B1 starting at screening, as determined by the Investigator.
6) Use of strong CYP3A4 inhibitors and inducers during participation in the trial, starting at the Screening Visit. Note: These medications include but are not limited to the following: Inhibitors: boceprevir, clarithromycin, cobicistat, dasabuvir, denoprevir, elvitegravir, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, and voriconazole. Inducers: apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John’s Wort.
7) Inadequate organ function including but not limited to:
a) Alanine aminotransferase (ALT) > 2x ULN.
b) Aspartate aminotransferase (AST) > 2x ULN.
c) Bilirubin direct > 1.25x ULN.
d) International normalized ratio (INR) > 1.2.
e) Clinically significant hepatic impairment defined as a Child-Pugh B or C.
f) Estimated glomerular filtration rate (eGFR) <60 mL/min.
8) Any clinically significant comorbidity or systemic dysfunction that, in the opinion of the Investigator, would jeopardize the safety of the subject by participating in the trial.
9) History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.
10) Known hypersensitivity to KVD824 or placebo or to any of the excipients.
11) Any prior use of any gene therapy treatment for HAE.
12) Participation in any interventional investigational clinical trial within 4 weeks of the last dosing of investigational drug prior to screening.
13) Any pregnant or breastfeeding subject.
14) Any subject who is currently stabilized under an indicated licensed HAE
prophylactic therapy.
15) Any subject who has previously had HAE attacks that were life threatening.
16) Any subject who is committed to an institution by virtue of an order issued by the judicial or the administrative authorities.
17) Any subject who is an employee of the study Sponsor or Investigator or who is a dependent of a Sponsor employee or an Investigator. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of this trial is the rate of Investigator-confirmed HAE attacks during the Treatment Period. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Proportion of subjects without Investigator-confirmed HAE attacks during the Treatment Period.
• Rate of Investigator-confirmed HAE attacks that require conventional treatment during the Treatment Period.
• Angioedema Quality of Life Questionnaire (AE-QoL) total score and domain scores during the Treatment Period.
• Angioedema Control Test (AECT) score and domain scores during the Treatment Period.
• Proportion of subjects with an AECT score ≥12 at the end of the Treatment Period. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
New Zealand |
United States |
France |
Bulgaria |
Romania |
Czechia |
Germany |
Italy |
Hungary |
North Macedonia |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 10 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 10 |